-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Downgrades Ultragenyx Pharmaceutical to In-Line, Lowers Price Target to $16

Benzinga·09/03/2026 12:15:47
Listen to the news
Evercore ISI Group analyst Liisa Bayko downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to In-Line and lowers the price target from $34 to $16.